Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWISS OPTICOV: Optimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
NCT07406217Phase 2Recruiting
- Sponsor
- Alexandra Calmy
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Modified Peptides, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of nirmatrelvir + ritonavir, remdesivir in coronavirus disease 2019 (COVID-19), sponsored by Alexandra Calmy. Started Apr 2023; status: recruiting.
02
Drugs
nirmatrelvir + ritonavirremdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07406217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406217.